Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Retrophin’s Stock Tumbles After Miss in Late-Stage Clinical Trial

Shares of Retrophin fell 27% after its rare disease drug candidate failed to work better than a placebo in a late-stage clinical study.

California Life Sciences Association Adds 9 Board Members

The California Life Sciences Association on Aug. 20 announced that it added nine board members, including from Amgen, DuPont Nutrition & Biosciences and Ernst & Young.

Heron’s Pain Anesthetic Successful in Late-Stage Clinical Trial

A postoperative pain anesthetic from Heron Therapeutics reduced pain intensity and the use of opioids among hernia surgery patients in a late-stage clinical trial, the company reported Aug. 20.

Scripps Mercy to Get $59 Million Cancer Center

Prebys Cancer Center Will Be Under Partnership With MD Anderson

SBP Lands $4.96M Grant In Hopes of Helping Oxygen-Deprived Newborns

A professor at Sanford Burnham Prebys Medical Discovery Institute landed a $4.96 million grant to further study a preclinical program for oxygen-deprived newborns at risk of neurological disorders.

SBP and Eli Lilly Extend Collaboration For 3 More Years

Complementary Expertise Being Applied to Develop Immunological Therapies

Organovo Exploring Strategic Alternatives After Poor Results

Company Suspended Development Of Its Lead Program

Ra Medical Announces Leadership Change

BIOTECH: CEO Irwin Is Out; CFO Jackson Named Interim Leader

Ra Medical Announces Leadership Change, Delays Results

BIOTECH: CEO Irwin Is Out; CFO Jackson Named Interim Leader

Amid legal, manufacturing and financial problems Ra Medical Systems delayed the release of second quarter results.

Tease photo

Biotechs (And Other Small Companies) May Lose Association Insurance Option

In a July letter to insurers the California Department of Managed Care, or CDMC, fired a warning shot against association health plans, in what could have wide-reaching impacts for biotechs, life sciences trade groups and other industries.

Tease photo

Cell Therapy Company Changes Name and Relocates HQ to Carlsbad

Lineage Underwent Corporate Restructuring, Co. to Focus on 3 Programs

BioTime is getting a new name — and a new headquarters.

Lyford Named to California’s Aging Stakeholder Advisory Committee

Shelley Lyford, the CEO of the nonprofit West Health, has been appointed to California’s Master Plan for Aging Stakeholder Advisory Committee.

Telemedicine Blossoming at San Diego Hospitals Amid Payment Reforms

Virtual Care Opens Lines Of Communication, Healing

Telemedicine is by no means new. But lagging insurance coverage and infrastructure costs prevented wide adoption. That’s changing,

Ionis’ Spinraza Gets Some Competition From Novartis’ SMA Treatment

Ionis Having Good Discussions With FDA on Other Therapeutic

Ionis Pharmaceuticals’ drug for a muscle-wasting disease continues to be the company’s main driver of growth, with competition looming.

Tease photo

Ra Medical Terminates CEO, Delays Q2 Results

Amid legal, manufacturing and financial challenges Ra Medical Systems delayed the release of second quarter results and fired its CEO.

Scripps Health Breaks Ground on $59M Cancer Center

A $59 million cancer center on the campus of Scripps Mercy Hospital that’s geared toward the central and southern parts of San Diego recently broke ground.

Q2 Life Sciences Footprint Expands By 263,399 Square Feet

Expansions By Some Of the Bigger Players Are Expected in Q3

The leasing footprint of San Diego life sciences companies grew by 263,399 square feet in the second quarter, according to report from the brokerage firm JLL.

Tease photo

Halozyme Reports Q2 Results

San Diego-based Halozyme reported $39.1 million in second quarter revenue, an 11% year-over-year increase.

Organovo Suspends Lead Program, to Explore ‘Strategic Alternatives’

Known for 3-D printed tissues that emulate human organs, Organovo plans to explore a merger, acquisition and other strategic alternatives.

Midstage Trial Results Hit Mark for Cidara’s Anti-Fungal Drug

CEO Says Treatment Is Now One Step Closer to the Market

A drug candidate from Cidara Therapeutics aimed at invasive fungal infections hit its mark in midstage clinical trial results, the company recently reported.

Tease photo

With Legal Issues Settled, Arcturus Focuses on Medicines

MEDICINE: RNA Delivery System Could Bring In $1B, Company has Drug Development Pipeline As Well

Arcturus Therapeutics went through a messy proxy fight last year that saw the removal and then return of its CEO. With that chapter behind it, the company is vying to be a frontrunner in what could be the next big thing in drug development.

Tease photo

Obalon Therapeutics Charts $15M Stock Offering

Obalon Therapeutics – which makes a gas-filled balloon designed to treat obesity -- recently announced it’s planning a $15 million public stock offering.

ResMed Reports Q4 Results, Takes $41M Hit In Justice Dept. Settlement

New Mask Launches, SaaS Solutions Seen As Positives For Company

In fourth quarter earnings medical device maker ResMed reported strong financial results, albeit dampened by a tentative $39.5 million settlement with the U.S. Justice Department.

Illumina Results Show Weak Second Quarter As Revenue Is Up 1%

CEO Is Confident in Competitive Position, Market And Opportunities

In second quarter earnings Illumina Inc. said revenue grew only 1% year over year, an atypical financial miss for the giant of DNA technology.

Q2: Revenue Skyrockets for Tandem Diabetes Care

After the market closed on Aug. 1 Tandem Diabetes Care reported second quarter earnings that included $93.3 million in revenue, a 173% year-over-year increase.

Top Four S.D. Life Sciences VC Deals Add Up To $379M

San Diego’s Total Q2 VC Share Comes To $805.8 Million

Life sciences companies dominated a list of the region’s largest venture capital investments in the second quarter.

Q2: Dexcom’s Revenue Rises 39%

In second quarter earnings Dexcom continued fast growth with a 39% year-over-year increase in revenue.

Cidara’s Drug Candidate Meets Clinical Trial Objectives

A drug candidate from Cidara Therapeutics aimed at invasive fungal infections hit its mark in midstage clinical trial results, the company recently reported.

Turning Point Names Yi Larson as CFO

Cancer drugmaker Turning Point Therapeutics has tapped investment banker Yi Larson as the company’s chief financial officer.

Acadia's Stock Drops After Weak Results in Schizophrenia Study

Study Sought to Expand Drug’s Indications; It Is Already Used in Parkinson’s

Acadia Pharmaceuticals recently said that its drug failed to improve the overall symptoms of schizophrenia compared with a placebo in a late-stage clinical trial.

Illumina’s Q2 Results Fall Short of Expectations

In second quarter earnings Illumina said revenue grew only 1% year over year, an atypical financial miss for the giant of DNA technology.

New CEO, $175M IPO Help Turning Point's Cancer Fight

MEDICINE: Strong Results Draws Investors

A class of drugs called tyrosine kinase inhibitors proved to be a breakthrough in cancer. But there’s a hitch: Tumors can develop resistance to the drugs.

Tease photo

ResMed Reports Q4 Earnings of $69M

San Diego-based ResMed reported $705 million in fourth quarter revenue, a 13% year-over-year increase.

Illumina Accelerator Chooses Cambridge As Its Second Location

Company Wants International Presence to Support Growing Ecosystem

An Illumina program that mentors and invests in early-stage genomics companies is expanding to the U.K.

Palomar, Graybill Medical Look at Possible Pact

HEALTH: Affiliations Seen As Way to Cut Costs, Avoid Duplications

Palomar Health wants to deepen ties with a decades-old private physician group in a bid to control costs and closely coordinate patient care.

Tease photo

Ligand Pharmaceuticals Buys Ab Initio Biotherapeutics for $12M

Ligand Pharmaceuticals – a San Diego biotech that helps pharmaceuticals discover and develop medicines – acquired Ab Initio Biotherapeutics for $12 million.

ViaCyte Adds Two Board Members

ViaCyte – a San Diego biotech working on stem cell-derived therapies for diabetes – added two members to its board: Paul Hastings and Ian Smith.

Acadia's Drug for Schizophrenia Falls Short of Expectations

Acadia Pharmaceuticals’ drug failed to improve the overall symptoms of schizophrenia compared with a placebo in a late-stage clinical trial.

Carlsmed Merges with Precisive Surgical

Carlsmed and Precisive Surgical are merging to develop personalized devices for spine surgery.

Financial Results ‘Disappoint’ Illumina, It Now Expects FY Revenue Growth of 6%

CEO Calls the Preliminary Results Transitory

Illumina analysts are still bullish on the company after a lowered revenue estimate prompted a stock sell-off.

Scripps Research Leading International Partnership For HIV Vaccine

NIH Division Will Provide Grant of $129 Million

An international partnership led by Scripps Research on July 10 pulled in a $129 million grant to bring a potential HIV vaccination into clinical testing.

Tease photo

These San Diego Biotechs Fell Hard, But Managed to Bounce Back

Biotechs recover momentum after being written off

Once pegged as goners, San Diego life sciences companies like Neurocrine, Arena Pharmaceuticals and Tandem Diabetes Care made comebacks. Their stories shed light on how to weather an industry in which companies expand and contract like an accordion based on clinical trial results.

Tease photo

Palomar, Graybill Medical Look at Possible Affliation

Graybill Medical Group and Palomar recently agreed to negotiate a formal affiliation agreement, a move that Palomar says isn’t so much about competition but nonetheless could ripple through North County’s health-care landscape.

Tease photo

Illumina Expands Startup Accelerator Program to the U.K.

An Illumina program that mentors and invests in early-stage genomics companies is expanding to the U.K.

Startups Claim Slice of a Changing Medical Device Market

HEALTH: $800 Billion Market Is Expected By 2030

The news coming out of San Diego’s medical device scene usually centers on the big dogs: Dexcom, ResMed and Nuvasive.

Alliance Healthcare Foundation Hires New Executive Director

Sarah Lyman has been hired as the executive director of the Alliance Healthcare Foundation, a nonprofit that provides grants to nonprofits that boost health care access for those in need.

Cradle Genomics Lands $17.1M Series A Round for Prenatal Testing

A startup led by former Illumina executives that wants to advance prenatal testing recently landed a $17.1 million series A round.

Trefoil Therapeutics Secures $28M Series A Round

San Diego biotech Trefoil Therapeutics recently brought in a $28 million series A round for work on vision diseases.

Analysts Stick By Illumina After Stock Sell-Off

Illumina analysts are still bullish on the company after a lowered revenue estimate prompted a stock sell-off.

StemoniX’s Growth Pushes It Into New Larger Facility

Its microOrgan Platform Provides More Human-Like Testing Opportunities

StemoniX — a San Diego biotech that grows micro organs from stem cells for drug testing — moved into a larger research facility this month.

Tease photo

Prev